Table 1.
Characteristics of 1951 Chronic Renal Insufficiency Cohort Study participants without pruritus at the baseline visit, stratified by baseline eGFR
| Characteristics | Overall | Estimated GFR (ml/min per 1.73 m2) | |||
|---|---|---|---|---|---|
| ≥60 | 45–59 | 30–44 | ≤29 | ||
| N (%) | 1951 | 402 (21) | 594 (30) | 632 (32) | 323 (17) |
| Demographic factors | |||||
| Mean age, yr (SD) | 58 (±11) | 53 (±11) | 58 (±11) | 59 (±11) | 58 (±11) |
| Female, N (%) | 853 (44) | 163 (41) | 239 (40) | 295 (47) | 156 (48) |
| Race/ethnicity, N (%) | |||||
| Non-Hispanic White | 854 (44) | 227 (56) | 265 (45) | 259 (41) | 103 (32) |
| Non-Hispanic Black | 805 (41) | 134 (33) | 238 (40) | 276 (44) | 157 (49) |
| Hispanic | 217 (11) | 18 (4) | 67 (11) | 77 (12) | 55 (17) |
| Other | 75 (4) | 23 (6) | 24 (4) | 20 (3) | 8 (2) |
| Kidney measures | |||||
| Mean eGFR (SD), ml/min per 1.73 m2 | 47 (±17) | 71 (±10) | 52 (±4) | 38 (±4) | 24 (±4) |
| Median urine protein (IQR), mg/gCr | 132 (54–622) | 63 (39–135) | 95 (50–313) | 220 (66–876) | 701 (148–2567) |
| Clinical factors | |||||
| Mean body mass index (SD), kg/m2 | 32 (±7) | 30 (±6) | 32 (±7) | 33 (±8) | 32 (±8) |
| Diabetes, N (%) | 886 (45) | 114 (28) | 253 (43) | 333 (53) | 186 (58) |
| Hypertension, N (%) | 1673 (86) | 276 (69) | 523 (88) | 575 (91) | 299 (93) |
| Coronary artery disease, N (%) | 378 (19) | 44 (11) | 110 (19) | 136 (22) | 88 (27) |
| Peripheral vascular disease, N (%) | 96 (5) | 7 (2) | 18 (3) | 41 (6) | 30 (9) |
| Congestive heart failure, N (%) | 132 (7) | 14 (3) | 26 (4) | 46 (7) | 46 (14) |
| Lung disease, N (%) | 249 (13) | 55 (14) | 73 (12) | 79 (12) | 42 (13) |
| Current smoking, N (%) | 237 (12) | 36 (9) | 63 (11) | 84 (13) | 54 (17) |
| Opioid use, N (%) | 178 (9) | 27 (7) | 52 (9) | 69 (11) | 30 (9) |
| Depressive symptoms, N (%) | |||||
| None (BDI 0–10) | 1582 (81) | 345 (86) | 496 (84) | 506 (80) | 235 (73) |
| Moderate (BDI 11–13) | 133 (7) | 20 (5) | 32 (5) | 48 (8) | 33 (10) |
| Severe (BDI ≥14) | 236 (12) | 37 (9) | 66 (11) | 78 (12) | 55 (17) |
| Mineral metabolism markers | |||||
| Mean serum calcium (SD), mg/dl | 9.2 (±0.5) | 9.2 (±0.4) | 9.2 (±0.4) | 9.3 (±0.5) | 9.2 (±0.5) |
| Mean serum phosphate (SD), mg/dl | 3.7 (±0.6) | 3.4 (±0.5) | 3.5 (±0.6) | 3.8 (±0.6) | 4.1 (±0.7) |
| Median intact PTH (IQR), pg/ml | 51 (33–83) | 34 (26–46) | 44 (31–66) | 61 (39–93) | 108 (65–177) |
| Hemoglobin | |||||
| Male: Mean hemoglobin (SD), g/dl | 13.2 (±1.8) | 14.1 (±1.4) | 13.4 (±1.7) | 12.9 (±1.6) | 12.0 (±1.7) |
| Female: Mean hemoglobin (SD), g/dl | 12.1 (±1.6) | 12.9 (±1.4) | 12.4 (±1.4) | 11.8 (±1.5) | 11.2 (±1.4) |
| Inflammatory markers | |||||
| Median hsCRP (IQR), mg/L | 2.3 (0.9–5.6) | 1.3 (0.7–3.3) | 2.4 (1.0–5.1) | 2.6 (1.1–6.4) | 2.8 (1.1–7.3) |
| Mean serum albumin (SD), g/dl | 4.0 (±0.5) | 4.1 (±0.4) | 4.0 (±0.5) | 3.9 (±0.4) | 3.8 (±0.5) |
| Median IL-6 (IQR), pg/ml | 1.7 (1.0–2.8) | 1.0 (0.7–1.7) | 1.6 (1.1–2.6) | 2.0 (1.3–3.1) | 2.5 (1.6–4.0) |
Groups compared using ANOVA, Kruskal-Wallis, or Pearson's chi-squared test as appropriate. All P for trend <0.05, with the exception of lung disease and opioid use. Missing: 1.5% serum calcium, 1.6% serum phosphate, 1.9% intact PTH, 0.4% hemoglobin, 0.1% hsCRP, 1.5% serum albumin, 1.5% IL-6. IQR, interquartile range; BDI, Beck's Depression Inventory; PTH, parathyroid hormone; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6.